Drugs / Chenodeoxycholic Acid
Chenodeoxycholic Acid
also known as
Acide chenodesoxycholique · Acido quenodeoxicolico · Chendol 125 · Chendol 250 · Chenocedon · Chenodeoxycholic acid leadiant (previously known as chenodeoxycholic acid sigma-tau) · Combidol · Lithofalk · +1 more
Small molecule targets NR1H4 via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) | — | 2017-04-10 | europa.eu ↗ |
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00004346 | Jan 1996 → ? | cerebrotendinous xanthomatosis | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06260748 | May 2024 → Nov 2025 | cerebrotendinous xanthomatosis | Leadiant Biosciences, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04270682 | Jan 2020 → Jul 2023 | — | Mirum Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT04640571 | Apr → Nov 2021 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT03059537 | Mar → Nov 2017 | disorder of metabolite absorption and transport | Lars Kristian Munck | Completed | No outcome recorded |
| Phase 4 | NCT02952963 | Oct 2016 → Dec 2017 | morbid obesity | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02876484 | Jun 2016 → Jun 2017 | morbid obesity | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02340247 | Nov 2014 → Apr 2015 | obesity disorder | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT01666223 | Nov 2012 → Jun 2013 | obesity disorder, type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT00018694 | Oct 1999 → Dec 2009 | cerebrotendinous xanthomatosis | US Department of Veterans Affairs | Withdrawn | No outcome recorded |
| — | NCT00004442 | ? → Apr 1999 | Zellweger spectrum disorders, adrenoleukodystrophy, d-bifunctional protein deficiency | University of Cincinnati | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00465751 Comparator | Oct 2004 → ? | familial hyperlipidemia, hypertriglyceridemia 2, metabolic syndrome X | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02314208 Comparator | Jan 2015 → Sep 2017 | hereditary spastic paraplegia | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03168555 Background | Jun 2017 → May 2019 | cholelithiasis, malabsorption syndrome | Zealand University Hospital | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | chenodeoxycholic acid | “A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis” NCT04270682 ↗ |
| Known as | Acide chenodesoxycholique | ChEMBL registry synonym — accepted as the source's own label CHEMBL240597 ↗ |
| Known as | Acido quenodeoxicolico | ChEMBL registry synonym — accepted as the source's own label CHEMBL240597 ↗ |
| Known as | Chendol 125 | ChEMBL registry synonym — accepted as the source's own label CHEMBL240597 ↗ |
| Known as | Chendol 250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL240597 ↗ |
| Known as | Chenocedon | ChEMBL registry synonym — accepted as the source's own label CHEMBL240597 ↗ |
| Known as | Chenodeoxycholic acid leadiant (previously known as chenodeoxycholic acid sigma-tau) | ChEMBL registry synonym — accepted as the source's own label CHEMBL240597 ↗ |
| Known as | Combidol | ChEMBL registry synonym — accepted as the source's own label CHEMBL240597 ↗ |
| Known as | Lithofalk | ChEMBL registry synonym — accepted as the source's own label CHEMBL240597 ↗ |
| Known as | Xenbilox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314208 ↗ |
| Action | Activate | “Bile acid receptor FXR agonist” CHEMBL240597 ↗ |
| Action | Inhibit | “replacement of chenodeoxycholic acid in the enterohepatic pool inhibit abnormal bile acid synthesis” NCT00018694 ↗ |
| Modality | Small molecule | — CHEMBL240597 ↗ |
| Route | Oral | “oral cholic acid and oral chenodeoxycholic acid on day 1” NCT00004442 ↗ |
| Target | NR1H4 | “Bile acid receptor FXR agonist” CHEMBL240597 ↗ |